Recruiting

Viral InfectionsViral Infections in Healthy and Immunocompromised Hosts

Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Code:

NCT01306084

Conditions

Anogenital Herpes

COVID-19

Herpes Labialis

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Accepted

Study Details

Brief summary:

Background:

\- Viral infections are an important cause of illness and death in hospitalized patients as well as outpatients. New strains of viruses may appear and infect both healthy people and those with weak immune systems. A better understanding of these new virus strains (such as SARS-CoV-2, the virus that causes COVID-19) may help to control and prevent these infections. In particular, some viral infections that are less problematic in healthy persons can be life threatening in persons with weak immune systems, and viruses may be able to evolve more rapidly in persons with weak immune systems and therefore develop resistance to existing treatments. Researchers are interested in collecting samples and information from otherwise healthy persons or persons with weak immune systems to study the effects of viruses and their development.

Objectives:

\- To collect samples and data from individuals who have been exposed to or have contracted viral infections.

Eligibility:

Individuals of all ages who have been diagnosed with a viral infection are suspected to have a viral infection, or have been in close contact with someone with a suspected or actual viral infection that is of interest to investigators in the Laboratory of Infectious Diseases.
Healthy persons and persons with weak immune systems (immunocompromised individuals) are eligible to participate.

Design:

Participants will be pre-screened to determine if they meet the eligibility criteria for the trial.
If eligible, evaluation may include a medical chart review, a history and physical examination, review of clinical reports from outside hospitals and laboratories, and review of tissue biopsies.
Study procedures may include collection of blood, urine, saliva, nasal fluid sampling, throat swabs, stool, and genital swabs. For participants who have specimens collected as part of their medical care (e.g. wound swabs, spinal tap, bronchoscopy, liver biopsy etc.), researchers may use leftover specimens from the clinical laboratory for testing.
Specimens may be collected up to 4 times per week during the first 2 weeks after enrollment, and then as many as 2 times per week for up to 2 years. Some participants may be asked to continue providing specimens if there is concern for relapse or recurrence of the infection.
Treatment is not offered under this study.

Conditions

Anogenital Herpes

COVID-19

Herpes Labialis

Study ID

NCT01306084

Start date

Mar 15, 2011

Status verified date

Sep 10, 2026

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Accepted

INCLUSION CRITERIA

1. The protocol is open to people of all ages;

1. Only patients greater than or equal to 2 years of age can be enrolled at the Clinical Center.
2. Patients who are less than 2 years old may be enrolled only remotely and will not be seen at the Clinical Center.
2. a. Persons having (or be suspected of having) a viral infection that is of interest to LID investigators.

b. Persons that are a close contact of someone who has (or is suspected of having) a viral infection that is of interest to LID investigators or is about to receive or have recently received a viral vaccine.

c. Persons that may have had a recent viral infection that is of interest to LID investigators that has since cleared

d. Healthy persons who will serve as controls for (a), (b), or (c) above. These persons will be 18 years of age or older and able to provide informed consent.
3. Adults who are unable to provide initial consent may be enrolled providing procedures per Human Research Protections Program (HRPP) Policy 403 have been followed.
4. Only subjects that are NIH employees or contractors who work at NIH will be enrolled in the COVID19 antibody cohort study on this protocol.

EXCLUSION CRITERIA

1. Patients who are unable to safely undergo study procedures and tests.
2. Patients unwilling to have samples collected and stored for future use.
3. For the healthy controls cohort: persons who are <18 years old, decisionally impaired adults, and pregnant women

Study Design

Enrollment

1000 participants

Anticipated

Interventions and Outcome Measures

Arms

NIH campus employees who have recently recovered from COVID-19

Clinical Center health care workers and ancillary staff who have close patient contact and possible exposures to SARS-CoV-2

Healthy and immunocompromised subjects who have or are suspected to have a viral infection

Healthy and immunocompromised subjects exposed to someone who has a viral infection or is suspected of having a viral infection

Healthy subjects who grew up in dengue endemic areas.

Healthy subjects with a history of viral hepatitis

Primary outcome measure

Sample collection, analysis of immune function, or review of tissue biopsies or clinical reports from outside laboratories in designated populations with viral infections, suspected of having a viral infection, recovered from a viral infection o... [ Time Frame: open-ended ]

Central Contacts and Locations

Central contacts

Jeffrey I Cohen, M.D.

(301) 496-5265 jcohen@niaid.nih.gov

Locations

National Institutes of Health Clinical Center

Recruiting

Bethesda, Maryland, United States, 20892

More Information

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Last update posted

Sep 14, 2026

Last verified

Sep 10, 2026

Keywords

SARS-CoV-2
Respiratory Infections
Norovirus
Adenovirus
Coronavirus
Natural History
Viral Infection
Respiratory Viruses

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-17. This information was provided to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID) on 2026-09-14. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.